Publications

Journal Article Ppublish 3 citations
Electronic publication date
September 29, 2015

View on Pubmed.gov 25427174 | View on doi.org 10.4161/1942086...

Surrogate target cells expressing surface anti-idiotype antibody for the clinical evaluation of an internalizing CD22-specific antibody.

Search for publications in this journal MAbs - 7(1):66-76

  • Shui-On Leung

    Search for this expert
    1
  • Kai Gao
  • Guang Yu Wang

    Search for this expert
  • Benny Ka-Wa Cheung

    Search for this expert
  • Kwan-Yeung Lee

    Search for this expert
  • Qi Zhao
  • Wing-Tai Cheung
  • Jun Zhi Wang

    Search for this expert

Abstract

SM03, a chimeric antibody that targets the B-cell restricted antigen CD22, is currently being clinically evaluated for the treatment of lymphomas and other autoimmune diseases in China. SM03 binding to surface CD22 leads to rapid internalization, making the development of an appropriate cell-based bioassay for monitoring changes in SM03 bioactivities during production, purification, storage, and clinical trials difficult. We report herein the development of an anti-idiotype antibody against SM03. Apart from its being used as a surrogate antigen for monitoring SM03 binding affinities, the anti-idiotype antibody was engineered to express as fusion proteins on cell surfaces in a non-internalizing manner, and the engineered cells were used as novel "surrogate target cells" for SM03. SM03-induced complement-mediated cytotoxicity (CMC) against these "surrogate target cells" proved to be an effective bioassay for monitoring changes in Fc functions, including those resulting from minor structural modifications borne within the Fc-appended carbohydrates. The approach can be generally applied for antibodies that target rapidly internalizing or non-surface bound antigens. The combined use of the anti-idiotype antibody and the surrogate target cells could help evaluate clinical parameters associated with safety and efficacies, and possibly the mechanisms of action of SM03.

References

Lancet Oncol. 2012 Apr;13(4):403-11

J Immunol. 1989 Oct 15;143(8):2595-601

Cell Mol Life Sci. 2013 Apr;70(8):1319-34

J Pharm Sci. 2007 Jan;96(1):1-26

Cited by 3 citations (total)

Clinical Trial, Phase I Journal Article Multicenter Study

Pharmacokinetics, Pharmacodynamics and Preliminary Observations for Clinical Activity and Safety of Multiple Doses of Human Mouse Chimeric Anti-CD22 Monoclonal Antibody (SM03) in Chinese Patients with Systemic Lupus Erythematosus.

Electronic publication date January 4, 2017

Search for publications in this journal Clin Drug Investig

Qian Zhao [...] Pei Hu et al.

BACKGROUND AND OBJECTIVES

SM03 is a novel recombinant, human/mouse chimeric immunoglobulin G1 monoclonal antibody directed against the CD22 antigen on human B lymphocytes....

Journal Article Review

Advantages and applications of CAR-expressing natural killer cells.

Electronic publication date March 3, 2015

Search for publications in this journal Front Pharmacol

Wolfgang Glienke [...] Ulrike Koehl et al.

In contrast to donor T cells, natural killer (NK) cells are known to mediate anti-cancer effects without the risk of...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances